DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avastin (Bevacizumab) - Published Studies

 
 



Avastin Related Published Studies

Well-designed clinical trials related to Avastin (Bevacizumab)

A randomized trial of bevacizumab for newly diagnosed glioblastoma. [2014]

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. [2013]

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. [2013]

Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. [2013]

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. [2013]

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). [2012]

Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection. [2012]

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. [2012]

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. [2012]

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium: A Pilot Study. [2011.11.10]

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. [2011.11.10]

A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. [2011.11]

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. [2011.10.20]

Intravitreal Bevacizumab for Treatment of Subfoveal Idiopathic Choroidal Neovascularization: Results of a 1-Year Prospective Trial. [2011.10.06]

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. [2011.07.01]

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. [2011.07]

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. [2011.07]

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. [2011.07]

Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. [2011.07]

Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. [2011.06.01]

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. [2011.06]

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. [2011.06]

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. [2011.06]

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. [2011.06]

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. [2011.06]

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. [2011.05.28]

Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration. [2011.05.11]

Safety and Efficacy of Using Off-label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single-site Phacotrabeculectomy by a Randomized Controlled Clinical Trial. [2011.05.03]

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. [2011.05]

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. [2011.04.01]

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. [2011.04]

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. [2011.04]

Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. [2011.03.01]

Adjunctive bevacizumab in patients undergoing Ahmed valve implantation: a pilot study. [2011.03]

Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. [2011.03]

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. [2011.02.17]

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. [2011.02.01]

Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. [2011.02]

Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). [2011.02]

Bevacizumab and ocular wound healing after primary pterygium excision. [2011.02]

Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. [2011.01]

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. [2011.01]

Incorporation of bevacizumab in the primary treatment of ovarian cancer. [2011]

Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. [2011]

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. [2011]

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. [2011]

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. [2011]

Haematologic toxicities associated with the addition of bevacizumab in cancer patients. [2011]

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. [2011]

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). [2010.12]

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [2010.11]

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. [2010.10.11]

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). [2010.10]

Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? [2010.09.30]

Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. [2010.09]

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). [2010.08.01]

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. [2010.07.10]

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. [2010.07.01]

Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. [2010.07]

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. [2010.06.09]

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. [2010.06]

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. [2010.06]

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. [2010.06]

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. [2010.05.01]

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. [2010.05.01]

Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. [2010.05]

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. [2010.05]

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. [2010.04.15]

Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. [2010.04]

Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. [2010.04]

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema. [2010.04]

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. [2010.03]

Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. [2010.03]

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. [2010.02.20]

Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. [2010.02]

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. [2010.02]

Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. [2010.02]

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. [2010.02]

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. [2010.02]

Bevacizumab safety in patients with central nervous system metastases. [2010.01.01]

Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. [2010.01]

Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. [2010]

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. [2010]

Preliminary results of subconjunctival bevacizumab in primary pterygium excision. [2010]

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. [2010]

[Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations]. [2010]

Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. [2010]

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). [2010]

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. [2010]

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. [2010]

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. [2009.12]

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. [2009.10.20]

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. [2009.10.06]

Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. [2009.10.02]

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. [2009.10.01]

Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. [2009.10]

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. [2009.10]

Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. [2009.10]

Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. [2009.09]

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. [2009.07.10]

Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. [2009.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014